Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSP105 peptide-pulsed dendritic cell vaccine - Medinet

Next Previous
Drug Profile

HSP105 peptide-pulsed dendritic cell vaccine - Medinet

Alternative Names: Cytotoxic T-lymphocyte stimulants-based cancer vaccine - Medinet; Dendritic cell-stimulated vaccine - Medinet; Heat shock protein 105 peptide-pulsed dendritic cell vaccine - Medinet; HSP105-derived cancer antigen peptide vaccine - Medinet

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medinet
  • Developer Medinet; University of Tokyo
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer
  • No development reported Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Renal-cell-carcinoma(Combination therapy, Late-stage disease) in Japan (Parenteral)
  • 15 Nov 2011 Phase-II clinical trials in Cancer (late-stage disease) in Japan (Parenteral) (UMIN000006730)
  • 31 Mar 2009 Medinet acquires a licence to patents for HSP105-derived peptides from Kumamoto Technology and Industrial Foundation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top